The purpose of this study is to assess the tolerance and efficacy of mobilizing hematopoietic stem cells after a single injection of plerixafor (0.24mg/kg) in 3 adult patients affected by sickle cell disease.
More information: clinicaltrials.gov, ITHANET Clinical Trials